NeuClone, Serum India Sign Global Licensing Deal For 10 Biosimilars
This article was originally published in PharmAsia News
Executive Summary
The Serum Institute of India and NeuClone have signed a licensing agreement for the Australia-based biotech to combine its cell-line development platform with the India firm's biologics expertise to produce 10 biosimilar monoclonal antibodies.